News

Cardica received the fourth and final milestone payment of $500,000 for the delivery of the Cook Vascular Closure Device (CVCD), an innovative automated system designed to close access

The round included lead investor Three Arch Partners and returning investors Versant Ventures and De Novo Ventures. Laurent Schaller, president and CEO of Benvenue Medical, said: “This financing

Patients in the initial 10 mcg/kg Maxy-G34 cohort met the safety criterion for duration of neutropenia (less than or equal to five days of severe neutropenia). No serious

The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine. The primary objective of the study is to assess the efficacy of MORAb-009

Under the terms of the agreement Osiris will immediately regain worldwide rights to its stem cell technology for all cardiovascular indications. In exchange, Osiris has agreed to relieve

The co-promotion will begin during the first quarter of 2008. Cephalexin, the generic form of Keflex, is said to be the number-one recommended oral antibiotic therapy for uncomplicated

The subjects in the Cethrin Phase I/IIa trial suffered a complete thoracic or cervical spinal cord injury (SCI) and were thus classified as an A on the American

The Empower study is a randomized, double-blind, placebo-controlled study and will include up to 220 patients across 15 clinical sites in the US and Australia. The company expects

The objective of the Phase IIb study is to compare the efficacy of PDX to that of Tarceva. The primary endpoint of the study is overall survival. Secondary